Futura Medical plc, a pharmaceutical company developing sexual health products, has announced that it has been granted an EU patent for its product MED3000, providing protection until 2040 in all European markets. The company is also continuing to prosecute patent applications in other key erectile dysfunction (ED) markets, including the US, to provide wider patent protection. James Barder, CEO of Futura, stated that the allowance of this patent application further strengthens the intellectual property of MED3000 as the company supports the roll-out of the product worldwide. He also emphasized the importance of this next step in growing the business and strengthening the Eroxon® brand.